Hexagon Capital Partners LLC Has $580,000 Stock Position in Novo Nordisk A/S (NYSE:NVO)

Hexagon Capital Partners LLC raised its stake in Novo Nordisk A/S (NYSE:NVO) by 23.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,605 shares of the company’s stock after buying an additional 1,059 shares during the period. Hexagon Capital Partners LLC’s holdings in Novo Nordisk A/S were worth $580,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Clarius Group LLC boosted its position in Novo Nordisk A/S by 0.5% in the fourth quarter. Clarius Group LLC now owns 18,505 shares of the company’s stock valued at $1,914,000 after buying an additional 93 shares in the last quarter. Tradewinds Capital Management LLC raised its stake in shares of Novo Nordisk A/S by 2.0% during the fourth quarter. Tradewinds Capital Management LLC now owns 4,955 shares of the company’s stock valued at $513,000 after acquiring an additional 95 shares during the last quarter. Relyea Zuckerberg Hanson LLC raised its stake in shares of Novo Nordisk A/S by 3.2% during the fourth quarter. Relyea Zuckerberg Hanson LLC now owns 3,159 shares of the company’s stock valued at $327,000 after acquiring an additional 99 shares during the last quarter. Fort Washington Investment Advisors Inc. OH raised its stake in shares of Novo Nordisk A/S by 3.5% during the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 2,960 shares of the company’s stock valued at $306,000 after acquiring an additional 100 shares during the last quarter. Finally, Highlander Capital Management LLC raised its stake in shares of Novo Nordisk A/S by 0.4% during the fourth quarter. Highlander Capital Management LLC now owns 25,100 shares of the company’s stock valued at $2,597,000 after acquiring an additional 100 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

NVO has been the subject of several analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. UBS Group assumed coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating for the company. BMO Capital Markets assumed coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They set an “outperform” rating and a $163.00 target price for the company. Finally, Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price for the company. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Stock Up 1.1 %

NVO traded up $1.40 during midday trading on Tuesday, hitting $128.28. The company had a trading volume of 7,835,414 shares, compared to its average volume of 4,800,112. Novo Nordisk A/S has a 52 week low of $75.56 and a 52 week high of $138.28. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $575.66 billion, a price-to-earnings ratio of 47.42, a PEG ratio of 2.12 and a beta of 0.41. The stock’s 50 day moving average price is $127.05 and its 200 day moving average price is $112.58.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The firm had revenue of $9.51 billion during the quarter, compared to the consensus estimate of $9.14 billion. On average, research analysts anticipate that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were issued a dividend of $0.664 per share. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a dividend yield of 0.9%. The ex-dividend date was Friday, March 22nd. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 49.17%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.